Revised SPC: Xtandi (enzalutamide) film coated tablets

SPC –details licence extension for use in metastatic hormone-sensitive prostate cancer; and warnings regarding risk of second primary malignancies and severe cutaneous adverse drug reactions (ADR). Dysgeusia has been added as an ADR (frequency common).

electronic Medicines compendium